Inside this article
A useful treatment journal needs more detail than “I tried Hims.” The product in this entry is Hims Tadalafil + Vardenafil Hard Mints: a tadalafil/vardenafil mint described in Hims safety information. Keeping that identity intact lets you distinguish a change in medicine from a change in packaging, service or expectations. The public records provide a starting point; they do not describe your eventual response.
Availability: Documented in the safety library; current sale availability unverified.
The exact product
Create a baseline entry before comparing experiences. The distinctive feature of this offer is two PDE5 inhibitors, including vardenafil. Write the dispensed name and label details separately from the words in an advertisement. A future change in flavor, strength or ingredients can otherwise disappear behind the same familiar brand name. The fact record below identifies the reviewed listing without recommending a dose or telling you how to administer it.
| Provider | Hims |
|---|---|
| Listed active ingredients | Tadalafil + vardenafil |
| Dosage form | Compounded combination mint |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Hims: Hard Mints formulation safety library · Hims: current ED treatment catalog |
Price, supply and payment
The financial entry should record the payment date as well as the price. For Hims Tadalafil + Vardenafil Hard Mints, the public starting point is Current plan price not verified. Keep a copy of the quantity and commitment attached to your own quote. If you later change products, this record helps distinguish a new prescription charge from a scheduled renewal. It also makes unused supply visible instead of treating every allocated dose as a successful treatment occasion.
| Public documentation | Hard Mints formulation safety library |
|---|---|
| Current price | Not verified for a matching selectable plan |
| Not 3-in-1 Hard Mints | Different PDE5 pair from sildenafil/tadalafil/B12 |
| Additional assessment | Vardenafil makes rhythm-history review relevant |
What the research can support
Separate a research note from a personal observation. Here the published evidence concerns individual-drug information; sildenafil/tadalafil studies do not test this pair; it leaves finished-product comparative evidence and account availability unresolved. Your experience can be important to a clinician without becoming a controlled comparison. Likewise, a provider survey cannot tell you in advance how you will respond. Record the source and its limits beside the claim so that a memorable headline does not become the entire evidence entry.
| Evidence boundary | individual-drug information; sildenafil/tadalafil studies do not test this pair |
|---|---|
| Not established here | finished-product comparative evidence and account availability |
| Clinical and regulatory references | MedlinePlus: Vardenafil · Cui et al. (2015): daily tadalafil with as-needed sildenafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil · MedlinePlus: Tadalafil |
Safety questions for the prescriber
The medication-history page belongs next to this product entry. Include other ED medicines, nitrates or nitrites, riociguat, blood-pressure treatment and medicines used only occasionally. Add relevant heart, kidney, liver or eye history. Do not experiment with overlaps or changes to isolate a side effect yourself. For a prescription such as Hims Tadalafil + Vardenafil Hard Mints, an accurate account of what was taken and when is more useful than a guess about the ingredient responsible.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|---|
| Vardenafil | QT/rhythm history and interacting medicines need explicit review. |
Availability and the actual prescription
Date the access information too. The current documentary finding is: Documented in the safety library; current sale availability unverified. A product can remain mentioned online after its enrollment rules change. If an account message differs from an article, save both and ask which applies to the proposed prescription. Do not record a public listing as a completed eligibility decision, and do not mistake a pharmacy dispatch estimate for the whole clinical assessment period.
Refills, changes and cancellation
Keep follow-up entries factual: the original concern, the prescribed product, whether its directions were followed, and the response or unwanted effect. A useful prompt specific to this entry is “What evidence and monitoring support this specific two-drug combination?” Write down the clinician's answer and the plan for reassessment. Billing notes belong alongside this history but do not replace it; postponing a shipment is not necessarily a medical instruction to stop a treatment.
| Next charge | The next order date is the charge/processing date; a first refill can be scheduled early. |
|---|---|
| Cancellation notice | At least 48 hours before the next order, according to support guidance. |
| Already processing | Ending a subscription does not cancel an order already processing or shipped. |
| Refund boundary | No refund guaranteed after pharmacy processing. |
| Policy sources | Hims Support: canceling a subscription · Hims Support: refund policy · Hims Support: when billing occurs |
Compare named products
The neighboring reviews are useful for explaining what changed between two offers. Compare a formulation field or payment interval instead of collecting general brand impressions. If you discuss a switch, retain the old entry so the prescriber can see the sequence. Do not translate that sequence into a claim that one product is universally better: symptoms, instructions, concurrent medicines and expectations may have changed as well.
Questions to keep with the offer
A good record includes uncertainty. Mark an unverified current plan or missing study as unverified, rather than filling the space with a testimonial. This entry is based on public documents and is not medically reviewed. We have not obtained Hims Tadalafil + Vardenafil Hard Mints as patients, inspected the supplied medicine or checked individual outcomes. The purpose is to make the next conversation more precise and the written history easier to use.
| Ask about this formula | What evidence and monitoring support this specific two-drug combination? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
The sources behind this page
Public material checked October 7, 2026. Provider pages describe advertised products and terms; they do not independently establish treatment quality.
- Hims: Hard Mints formulation safety libraryProvider formulation document; includes options not confirmed in the main catalog
- Hims: current ED treatment catalogProvider catalog; individual named offers and starting prices
- MedlinePlus: VardenafilGovernment patient drug information; standard products, not compounded equivalents
- Hims Support: canceling a subscriptionProvider policy; 48-hour notice and orders already processing
- Hims Support: refund policyProvider policy; no guaranteed refund after pharmacy processing
- Hims Support: when billing occursProvider policy; next order date, charge timing, and subscription intervals
- Hims Support: changing the next order dateProvider support; refill rescheduling differs from cancellation
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- MedlinePlus: SildenafilDrug information; standard sildenafil products
- MedlinePlus: TadalafilDrug information; standard tadalafil products